
FDA Probes Cause of Failed Johnson & Johnson Covid-19 Vaccine Batch
Scrutiny follows drugmaker’s disclosure that it scrapped distribution of doses after an ingredient didn’t meet quality standards at a contract manufacturing facility
Scrutiny follows drugmaker’s disclosure that it scrapped distribution of doses after an ingredient didn’t meet quality standards at a contract manufacturing facility
Joining us is Dr. Julie Swann from North Carolina State University, a faculty member who specializes in medical supply chains, and Dr. Robert Frank from the Center for Vaccine Research and Cincinnati Children's Hospital.
CATONSVILLE, MD, April 1, 2021 – Online marketers have seen the pattern: 95%-98% of online visitors search for something, but the search never converts into a purchase and they leave the site without buying. For marketers, this results in speculation and assumptions that can lead to wasted time and investments in ineffective marketing programs.
A Baltimore company trying to produce COVID-19 vaccines had to throw out a bad batch of the Johnson & Johnson product. That sets back efforts to expand production of this vaccine.
Human errors at a manufacturing plant forced Johnson & Johnson to throw out 15 million doses of its COVID-19 vaccine – enough to vaccinate 7% of the U.S. adult population.
Jeff Cohen
Chief Strategy Officer
INFORMS
Catonsville, MD
[email protected]
443-757-3565
An audio journey of how data and analytics save lives, save money and solve problems.
With seemingly no limit to the demand for artificial intelligence, everyone in the energy, AI, and climate fields is justifiably worried. Will there be enough clean electricity to power AI and enough water to cool the data centers that support this technology? These are important questions with serious implications for communities, the economy, and the environment.
It’s college graduation season, which means over 4 million seniors will graduate in the next few weeks, flooding the job market with new candidates. One area that has shown high potential for the right candidates is artificial intelligence and machine learning. Both disciplines are part of the larger data and analytics career path.
Drugs being explicitly developed to treat rare diseases are getting more expensive.
Robert F. Kennedy Jr., as the new secretary of Health and Human Services, is the nation’s de facto healthcare czar. He will have influence over numerous highly visible agencies, including the Centers for Disease Control and Prevention, the National Institutes of Health and the Food and Drug Administration, among others. Given that healthcare is something that touches everyone’s life, his footprint of influence will be expansive.
The recent US-China agreement to temporarily reduce tariffs is a major step for global trade, with tariffs on US goods entering China dropping from 125% to 10% and on Chinese goods entering the US decreasing from 145% to 30% starting May 14. While this has boosted markets and created optimism, key industries like autos and steel remain affected, leaving businesses waiting for clearer long-term trade policies.
With sweeping new tariffs on Chinese-made products set to take effect this summer, Americans are being urged to prepare for price hikes on everyday goods. President Donald Trump's reinstated trade policies are expected to affect a wide swath of consumer imports, including electronics, furniture, appliances, and baby gear. Retail experts are advising shoppers to act before the tariffs hit and prices rise.
Twenty years ago, few people would have been able to imagine the energy landscape of today. In 2005, US oil production, after a long decline, had fallen to its lowest levels in decades, and few experts thought that would change.
In the case of upgrading electrical and broadband infrastructure, new analysis from the University of Massachusetts Amherst reveals {that a} “dig once” strategy is almost 40% more economical than changing them individually.